{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:35Z","timestamp":1791910655532,"version":"4.3.4"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011338","name":"AZ","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The relative safety and efficacy of de-escalation, extended duration (ED) (&amp;gt;12-months), and standard dual antiplatelet therapy for 12-months (DAPT-12) in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) remains controversial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Online databases were queried to identify relevant randomized control trials (RCTs). ED-DAPT, high-potency (HP) DAPT, shorter duration (SD) DAPT, and low-dose (LD) DAPT were compared with DAPT-12. A trial sequential, bivariate, influential, and frequentist network meta-analysis (NMA) was performed to determine the pooled estimates. A total of 30 RCTs comprising 81\u00a0208 (40\u00a0839 experimental, 40\u00a0369 control arm) patients with CAD were included in the quantitative analysis. On NMA, compared with DAPT-12, all types of de-escalation, HP-DAPT-12, and ED-DAPT strategies had a statistically non-significant difference in the incidence of MACE at a median follow-up of 1-year. Similarly, there was no significant difference in the incidence of stroke, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), and all-cause mortality between DAPT-12 and all other strategies. The network estimates showed a significantly lower incidence of major bleeding with DAPT for 3-months followed by P2Y12-inhibitor monotherapy (RR 0.62, 95% CI 0.45\u20130.84), while a higher risk of bleeding with HP-DAPT for 12 months (RR 1.55, 95% CI 1.16\u20132.06). The net clinical benefit and rankograms also favoured DAPT-3 (P2Y12) and discouraged the use of HP-DAPT-12 and ED-DAPT. A subgroup analysis of 19 RCTs restricted to patients who presented with acute coronary syndrome (ACS) mirrored the findings of pooled analysis. A sensitivity analysis revealed no influence of any individual study or individual strategy on net ischemic estimates. The trial sequential analysis (TSA) illustrated a consistently non-significant difference at the interim analysis of trials, reaching the futility area for MACE, while the cumulative Z-values line surpassed the monitoring boundary as well as the required information size for major bleeding favouring de-escalation strategy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DAPT for three months followed by ticagrelor-only and use of aspirin\u00a0+\u00a0clopidogrel after a short period of high potency DAPT appears to be a safe strategy for treating post-PCI patients. However, given the methodological limitations and inclusion of a small number of trials in novel de-escalation strategies, these findings need validation by future large scale RCTs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvac020","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T20:14:41Z","timestamp":1647461681000},"page":"717-727","source":"Crossref","is-referenced-by-count":18,"title":["Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4850-0309","authenticated-orcid":false,"given":"Waqas","family":"Ullah","sequence":"first","affiliation":[{"name":"Division of Cardiology, Thomas Jefferson University Hospitals , 111 S 11th Street, Philadelphia , PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Zahid","sequence":"additional","affiliation":[{"name":"Rochester General Hospital , 1425 Portland Ave, Rochester, NY 14621 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harigopal","family":"Sandhyavenu","sequence":"additional","affiliation":[{"name":"Weiss Memorial Hospital , 4646 N Marine Dr, Chicago, IL 60640 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Faisaluddin","sequence":"additional","affiliation":[{"name":"Rochester General Hospital , 1425 Portland Ave, Rochester, NY 14621 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Khalil","sequence":"additional","affiliation":[{"name":"Sanford School of Medicine, University of South Dakota , 1400 West 22nd Street, Sioux Falls, SD 57105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad K","family":"Pasha","sequence":"additional","affiliation":[{"name":"UHS Wilson Hospital, 33-57 Harrison Street , Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Chadi","family":"Alraies","sequence":"additional","affiliation":[{"name":"Detroit Medical Center, Heart Hospital , 311 Mack Ave, Detroit, MI 48201 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[{"name":"Aix-Marseille University , 58 Boulevard Charles Livon, 13007 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil V","family":"Rao","sequence":"additional","affiliation":[{"name":"The Duke Clinical Research Institute , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[{"name":"Coll\u00e8ge National des Cardiologues Fran\u00e7ais , 13 Rue Ni\u00e9pce, 75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Savage","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Thomas Jefferson University Hospitals , 111 S 11th Street, Philadelphia , PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Fischman","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Thomas Jefferson University Hospitals , 111 S 11th Street, Philadelphia , PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2022092908585986000_bib1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience\/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"2022092908585986000_bib2","first-page":"1438","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong","year":"2016","journal-title":"JACC: Cardiovascular Interventions"},{"key":"2022092908585986000_bib3","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1093\/eurheartj\/ehv511","article-title":"Stent thrombosis and restenosis: what have we learned and where are we going? The andreas gr\u00fcntzig lecture ESC 2014","volume":"36","author":"Byrne","year":"2015","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib4","first-page":"93","article-title":"Prevention of stent thrombosis: challenges and solutions","volume":"11","author":"Reejhsinghani","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"2022092908585986000_bib5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2022092908585986000_bib6","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2022092908585986000_bib7","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2022092908585986000_bib8","author":"Dharam","year":"2022","journal-title":"Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention - TWILIGHT: American College of Cardiology"},{"key":"2022092908585986000_bib9","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"2022092908585986000_bib10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy","volume":"13","author":"Lee","year":"2018","journal-title":"EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology"},{"key":"2022092908585986000_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ahj.2016.04.016","article-title":"Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial","volume":"178","author":"Camaro","year":"2016","journal-title":"Am Heart J"},{"key":"2022092908585986000_bib13","first-page":"e003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han","year":"2016","journal-title":"Circulation: Cardiovascular Interventions"},{"key":"2022092908585986000_bib14","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib15","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"2022092908585986000_bib16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6\u00a0vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2017.02.015","article-title":"Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: rationale and study design of the prospective randomized multicenter IDEAL-LM trial","volume":"187","author":"Lemmert","year":"2017","journal-title":"Am Heart J"},{"key":"2022092908585986000_bib19","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial","volume":"14","author":"Hong","year":"2021","journal-title":"Cardiovascular Interventions"},{"key":"2022092908585986000_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib21","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib23","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib24","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation"},{"key":"2022092908585986000_bib25","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"2022092908585986000_bib27","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2022092908585986000_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"2022092908585986000_bib29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"Cardiovascular Interventions"},{"key":"2022092908585986000_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib32","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"2022092908585986000_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the european society of cardiology (ESC) and of the european association for cardio-thoracic surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2022092908585986000_bib36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2022092908585986000_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.amjcard.2020.04.027","article-title":"Meta-analysis of dual antiplatelet therapy versus monotherapy with P2Y12 inhibitors in patients after percutaneous coronary intervention","volume":"127","author":"Malik","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022092908585986000_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pcad.2020.03.018","article-title":"Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: a network meta-analysis of randomized controlled trials","volume":"63","author":"Garg","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2022092908585986000_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40261-020-00947-x","article-title":"P2Y12 inhibitor monotherapy after a short dual antiplatelet therapy versus standard-term dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a contemporary meta-analysis","volume":"40","author":"Ho","year":"2020","journal-title":"Clinical Drug Investigation"},{"key":"2022092908585986000_bib40","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"2022092908585986000_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11239-019-01985-9","article-title":"Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint","volume":"49","author":"Wernly","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2022092908585986000_bib42","first-page":"365:I2222","article-title":"Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis","author":"Xu","year":"2019","journal-title":"BMJ"},{"key":"2022092908585986000_bib43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/clc.23075","article-title":"Efficacy and safety of short-term dual antiplatelet therapy (\u2264 6 months) after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"41","author":"Misumida","year":"2018","journal-title":"Clin Cardiol"},{"key":"2022092908585986000_bib44","doi-asserted-by":"crossref","first-page":"e0174502","DOI":"10.1371\/journal.pone.0174502","article-title":"Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration","volume":"12","author":"Toyota","year":"2017","journal-title":"PLoS One"},{"key":"2022092908585986000_bib45","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet North Am Ed"},{"key":"2022092908585986000_bib46","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ccd.26653","article-title":"Short-versus long-term dual antiplatelet therapy after drug-eluting stent implantation in women versus men: a sex-specific patient-level pooled-analysis of six randomized trials","volume":"89","author":"Sawaya","year":"2017","journal-title":"Catheter Cardiovasc. Interv."},{"key":"2022092908585986000_bib48","first-page":"e004139","article-title":"Dual antiplatelet therapy continuation beyond 1 year after drug-eluting stents: a meta-analysis of randomized trials","volume":"10","author":"Ferrante","year":"2017","journal-title":"Circulation: Cardiovascular Interventions"},{"key":"2022092908585986000_bib49","first-page":"168","article-title":"Efficacy and safety of short-term (\u2264 6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials","volume":"17","author":"Xiang","year":"2017","journal-title":"Anatolian Journal of Cardiology"},{"key":"2022092908585986000_bib50","first-page":"e203","article-title":"Short duration vs. standard duration of dual-antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents\u2014a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"28","author":"Wassef","year":"2016","journal-title":"J Invasive Cardiol"},{"key":"2022092908585986000_bib51","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ccd.25520","article-title":"Shorter (\u2264 6 months) versus longer (\u226512 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials","volume":"85","author":"Pandit","year":"2015","journal-title":"Catheter Cardiovasc. Interv."},{"key":"2022092908585986000_bib53","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacc.2014.06.1158","article-title":"Short versus long duration of DAPT after DES implantation: a meta-analysis","volume":"64","author":"Stefanini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022092908585986000_bib54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"2022092908585986000_bib55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet North Am Ed"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvac020\/43521569\/pvac020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/7\/717\/46168362\/pvac020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/7\/717\/46168362\/pvac020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:01:17Z","timestamp":1664442077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/7\/717\/6553814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,3,24]]},"published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvac020","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,3,24]]}}}